Kornimate/medical-research-clean huggingface dataset:
individually tailored prophylaxis in patients with severe hemophilia a

Conditions: Hemophilia A

Summary: patients with severe haemophilia a lack clotting factor fviii and suffer from spontaneous and traumatic bleeds. in the absence of treatment, frequent bleeds in joints lead to severe joint destruction. in 1960s, prophylactic therapy was developed involving the infusion of clotting factor on a regular schedule in order to keep clotting levels sufficiently high to prevent spontaneous bleeding episodes. prophylaxis is started at an early age before the age of 2 years or after the first joint bleed. the malmö experience indicates that treatment is most effective when administered in large doses at least 3 times weekly. however, such an intensive treatment in young boys may be very difficult to carry out for home treatment. currently, there is no international recommendation on prophylactic therapy regimens. because of the high cost and limited availability of factor concentrates, dosing is an important issue in prophylaxis therapy. it was recently shown that 24 hours after fviii concentrate administration, in patients presenting similar fviiii levels, thrombin generation capacity may be significantly different. in addition, independently of the fviii level, a correlation was found between severe clinical bleeding phenotype and thrombin generating capacity. the aim of the present clinical study is to assess the thrombin generation test as the main surrogate marker to evaluate the coagulating capacity of haemophiliacs on prophylaxis regimen. optimizing prophylactic therapy to patient's phenotype with no loss of clinical effectiveness can significantly improve patients' quality of life, protect haemophilic children against arthropathy and possibly limit the cost of the prophylaxis therapy.


Eligibility criteria:
inclusion criteria: * severe haemophilia a (fviii \< 1 iu/dl) * currently on prophylactic therapy administered at least 3 times per week with a clinical efficiency * age: 6 - 45 years * adequate venous access in adults and children i.e. presence of 2 or more good quality peripheral veins, in order to avoid the need for a central venous device. one peripheral vein for fviii infusions and one other for blood sampling are required. * competent in home treatment and infusion therapy (patient or parents) * ability of patient or family (for minors) to give informed consent * patient affiliated to french social insurance system. exclusion criteria: * age \ 45 years * hemophilia a with documented history of inhibitor * clinically symptomatic liver disease (supported by e.g. diagnosis of cirrhosis, portal hypertension, ascites, pt \> 5 seconds above upper limit of normal) * platelet count \< 100x109/l * planned elective surgery within 13 months * poor venous access according inclusion criteria * presence of a documented target joint

Keywords: hemophilia a prophylaxis thrombin generation test (tgt)
remote ischemic conditioning in oncology

Conditions: Participants Undergoing Anthracycline Chemotherapy

Summary: this is a feasibility study at a single site, cincinnati children's hospital medical center. patients undergoing anthracycline chemotherapy for hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. the purpose of the study is to determine if performing remote ischemic conditioning (ric) is feasible in children and young adults receiving anthracycline chemotherapy. the secondary purpose is to describe differences in markers of myocardial injury and stress in children and young adults that receive ric prior to anthracycline chemotherapy compared to control subjects that receive sham therapy prior to chemotherapy.


Eligibility criteria:
inclusion criteria: 1. pediatric, adolescent, or young adult patients, 11 years of age or above. 2. able to tolerate upper arm blood pressure inflation. exclusion criteria: 1. previous diagnosis of cardiomyopathy (dilated, hypertrophic, restrictive, myocarditis) or congenital heart disease other than bicuspid aortic valve. 2. chronic kidney disease as defined as a pre-transplant gfr \<80 3. central line in both upper extremities. 4. known peripheral vascular disease or vasculitis. 5. platelet count less than 30,000. 6. known clotting disorder or hypercoagulability 7. non-english-speaking patients.
effects of qigong on type 2 diabetic patients

Conditions: Diabetes Mellitus, Type 2

Summary: qigong therapy is a subtle energy-based methodology for preventing and healing diseases that has been practiced with remarkable results in china for about five thousand years. recently, preliminary studies showed that qigong exercises improve insulin resistance and glucose metabolism in people with type 2 diabetes. these studies suggest that qigong therapy might be an effective and valuable complementary modality for treating type 2 diabetes. type 2 diabetes is a chronic disease marked by abnormally high levels of sugar in the blood. diabetes is a serious disease, which, if not controlled, can be life threatening. the purpose of this project is to conduct a randomized, controlled pilot clinical trial to compare the effectiveness of qigong therapy to mild exercise and conventional treatment in type 2 diabetes and to identify biological and psychological characteristics associated with subjects' responses to qigong therapy. aim 1: to compare the effects on blood sugar and hemoglobin a1c (hba1c) level between a qigong therapy group and non-treated control group as well as between qigong group and a progressive resistance training (prt) group before, during and after and 12-week intervention. hypothesis 1: both qigong therapy and prt will help type 2 diabetic patients reduce blood sugar levels to different degrees through improving insulin resistance. but the levels of reduction of blood sugar will be greater by qigong therapy than by prt due to enhanced insulin secretion. aim 2: to compare the effects on fasting c-peptide and insulin levels between a qigong therapy group, a prt group and a non-treated control group before and after the intervention. hypothesis 2: qigong therapy will increase the endogenous insulin and c-peptide levels by restoring the functions of the pancreas, while prt will not alter either insulin or c-peptide levels. aim 3: to compare the effects of qigong therapy and prt on blood cortisol levels and psychological stress levels before, during and after the intervention. hypothesis 3: perceived stress and depression will be improved by qigong therapy to a greater extent than by prt, and blood cortisol levels will be reduced to a greater extent with qigong therapy.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes defined as a glycohemoglobin between 7.5% and 10.5%, and fasting insulin level \<40 (iu/ml). * must be controlling their diabetes with diet or may be taking oral medication for at least three months * age 18-65 * ability to physically perform qigong or low-intensity physical exercise * body mass index 18-40 * have current primary care * willing to monitor blood glucose at least twice a day * willing to maintain a consistent diet during the study, and * sign informed consent exclusion criteria: * significant kidney, liver or heart disease * history of drug or alcohol abuse within the past 2 years * current or previous use of insulin * use of dietary supplements that affect blood glucose or insulin * current practice of qigong (any style)

Keywords: qigong breathing management glucose
an efficacy, safety and effects on quality of life of tramadol/paracetamol as add-on therapy in chronic osteoarthritis

Conditions: Osteoarthritis

Summary: the purpose of this study is to evaluate the efficacy, safety and effects on quality of life (qol) of tramadol/paracetamol (apap) as an add-on therapy (medication taken in addition to another medication) in filipino participants with chronic (lasting a long time) osteoarthritis (disorder, which is seen mostly in older persons, in which the joints become painful and stiff).

this is an open-label (all people know the identity of the intervention), randomized (study drug assigned by chance), controlled study to evaluate the efficacy, safety and effects on qol of tramadol/apap as an add-on therapy in filipino participants suffering from chronic pain because of chronic osteoarthritis. participants will be randomly assigned to 2 groups: tramadol/apap group and non tramadol/apap group. participants in tramadol/apap group will receive celecoxib 200 milligram (mg) and fixed dose combination of tramadol (37.5 mg)/apap (325 mg) as add on therapy, while the participants in non-tramadol/apap group will receive celecoxib 200 mg only. the total duration of the study will be 4 weeks. the participants in both the groups will be given celecoxib 200 mg once daily for 4 weeks. in addition, the participants in the tramadol/apap group will be given add-on tramadol/apap doses 3 times a day for 4 weeks. participants will be asked to return for follow-up at weeks 2 and 4. efficacy will be assessed using 100 millimeter (mm) visual analog scale (vas) while qol will be assessed using the oswestry disability index (odi). participant safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * diagnosed with chronic osteoarthritis of knee or hip for greater than (\>) or equal to (=) 1 year (based on the american college of rheumatology (acr) diagnostic criteria for osteoarthritis), who are experiencing at least moderate osteoarthritis pain (\>=50 millimeter \[mm\] in 100 mm visual analog scale \[vas\]) * on any cyclooxygenase - 2 (cox-2) inhibitors for at least 2 weeks preceding the study * women with childbearing potential must have negative pregnancy test * women of child bearing potential must agree to use accepted methods of contraception * participant has signed the written informed consent form exclusion criteria: * participants taking monoamine oxydase (mao) inhibitors, neuroleptics or drugs for seizures * severe hepatic impairment (the impaired ability of the liver to fulfill its role in metabolism) * on maintenance tramadol and/or paracetamol(apap) * on sedative hypnotics, short-acting analgesics, topical medications and anesthetics, and/or muscle relaxants * pregnant, lactating or breastfeeding participants

Keywords: osteoarthritis celecoxib tramadol paracetamol
low-dose chest computed tomography screening for lung cancer in survivors of hodgkin's disease

Conditions: Lung Cancer

Summary: this research study is being done because patients with a history of chest radiation treatment for hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment. the risk appears to be further increased among patients with a smoking history. currently, the practice is to recommend annual low-dose chest ct scans in survivors of hodgkin's disease who have received prior chest radiation treatment and who have at least a moderate smoking history. in this study, the ct scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner.

- participants will undergo a chest computed tomography (ct) scan once a year for a 3-year period.

Eligibility criteria:
inclusion criteria: * 5 years or longer from initial hodgkin's disease diagnosis * current age 18 or older * received mediastinal irradiation and/or alkylating-agent based chemotherapy * smoking history of 10-pack years or more, or current smoker * pre-approval from the participant's insurance company for the ct study exclusion criteria: * patients with a history of lung cancer * currently receiving treatment for another cancer diagnosis * known diagnosis of any metastatic cancer * pregnant women

Keywords: hodgkin's disease ct scan
evaluation of the effectiveness of aromatherapy on anxiety, vital signs, and postoperative complications in lower impacted wisdom tooth surgery

Conditions: Tooth, Impacted; Dental Anxiety

Summary: dental anxiety is considered to be one of the fears and concerns associated with dental treatment. lavender has a relaxing and anxiolytic aroma. the aim of this study was to evaluate the effects of aromatherapy on dental anxiety in bilateral impacted wisdom tooth surgery.


Eligibility criteria:
inclusion criteria: * bilateral wisdom tooth in mandible exclusion criteria: * lavender oil allergy * systemic disease * off-study drug use * smoking * pregnancy or breastfeeding

Keywords: aromatherapy lavender oil wisdom tooth extraction
comparison of cardiopulmonary fitness level with normal values after covid-19

Conditions: COVID 19

Summary: covid-19 (coronavirus disease 2019) is a new infectious disease caused by a virus named as sars-cov2 (severe acute respiratory syndrome coronavirus-2). although it can have a devastating effect on many organs, the respiratory tract is particularly affected. in the course of the disease, a wide clinical spectrum is observed, from flu-like illness to lung failure. some of the patients who survived the disease continue to have problems such as shortness of breath, fatigue, decrease in walking distance, decrease in participation in daily life activities. these problems suggest that the effects on respiratory and cardiac functions continue even after the disease ends. this study was designed to demonstrate the effects and extent of covid-19 on cardiopulmonary capacity.

aims of the research are that demonstrate change in cardiopulmonary fitness level in patients with covid-19 according to normal values and reveal the relationship of this change with age, gender, physical activity level, disease severity and accompanying medical conditions. patients older than 18 years old who are diagnosed with covid-19 according to clinical symptoms and rt-pcr test positivity and at least 30 days past the end of their symptoms are accepted for the study. according to world health organization's (who) classification, covid-19 disease severity is determined. physical activity level of the patients before covid-19 is evaluated with international physical activity questionnaire. risk of anxiety and depression of the patients is identified with hospital anxiety and depression scale (hads), which has 14 questions. to evaluate cardiopulmonary fitness level, cardiopulmonary exercise test (cpet) and 6-minute walk test are applied. cardiopulmonary exercise test is gold standard to determine cardiac and respiratory functions. pulmonary function test is performed to identify the conditions that affect the results of cardiopulmonary exercise test.

Eligibility criteria:
inclusion criteria: * diagnosis of sars-cov2 with a positive result of reverse polymerase-transcriptase chain reaction test * it must have been at least 30 days after symptoms of covid-19 improved. exclusion criteria: * 5 days after acute myocardial infarction * unstable angina * active endocarditis, myocarditis or pericarditis * symptomatic severe aortic stenosis * uncontrolled heart failure * acute pulmonary embolus, pulmonary infarction or thrombosis of lower extremities * suspected dissecting aneurysm * uncontrolled asthma * room air desaturation at rest (o2 ⩽85%) * respiratory failure * acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise * mental impairment * severe untreated arterial hypertension at rest (\>200 mm hg systolic, \>120 mm hg diastolic) * high-degree atrioventricular block * orthopaedic, neurological or systemic impairments that leading to inability to perform test

Keywords: cardiopulmonary exercise test exercise capacity covid 19 6 minute walk test
opiate craving reduction study using post-detox patients on suboxone and use of teas as adjunctive treatment

Conditions: Opioid-use Disorder

Summary: pilot study of 12 outpatients in early recovery from illicit drug use,post-detox and on buprenorphine-naloxone maintenance will be offered 12 teas adjunct treatments over 6 weeks(x2/week) to ascertain if they experience any improvement in mood,sleep,overall quality of life and decrease drug cravings ultimately while facing everyday life stressors.

* this crossover study will involve participants who will be randomized into two treatment groups,a\&b. teas treatments will be given for 30 minutes,x2/week,for 6 weeks(12total sessions). group a will receive 2 weeks(4 sessions) of active treatment followed by 4 weeks of sham treatment(8 sessions). group b will receive 2 weeks(4 sessions) of sham treatment,2 weeks (4 sessions)of real treatment,and finally 2 weeks (4 sessions) of sham treatment. * parameters to be measured include vital signs and questionnaires weeks 1,3,5,6 to assess self-reported past 14-day substance use,alcohol and drug craving,withdrawal symptoms,sleep,mood,pain and overall quality of life. * goals include better lives for post-detox opiate addicts as they incorporate this treatment into their lives,saving themselves and loved ones more horror,and their communities resources.

Eligibility criteria:
inclusion criteria: * 18-59 years old * early recovery(0-3months of abstinence * not currently detoxing * maintained on buprenorphine-naloxone under the care of qualified md * proficient in the english language exclusion criteria: * having acute,psychiatric symptoms which would pose safety concerns,or an adherence to treatment barrier(active suicidality/psychosis/mania) * severe cognitive disorders\*not competent to give informed consent * active cardiac disease or ekg abnormalities or with cardiac pacemaker * currently detoxing from alcohol or illicit drugs * inability or non-intention to attend all treatment sessions\*history of seizures\*pregnancy or breast feeding.
sulfur amino acids, energy metabolism and obesity

Conditions: Overweight and Obesity

Summary: the primary objective of the trial is to establish the effects of dietary sulfur amino acid (saa) restriction on body weight, body composition and energy expenditure in humans.

dietary saa restriction is an established model for increasing lifespan and improving metabolic health in animal studies. data from human studies are limited. in this study the investigators will perform an 8-week dietary intervention with saa restriction to characterise the effects on several parameters related to metabolic health including body weight, body composition, energy expenditure, lipid profile and gene expression profiles in adipose tissue. the aim is to translate findings from previous animal experiments to humans

Eligibility criteria:
inclusion criteria: * healthy participants with overweight and obesity (bmi 27-35 kg/m2) * waist circumference \> 80 cm for women and \> 94 cm for men exclusion criteria: * smoking * presence of chronic disease * established co-morbidities * already on a vegan diet or have been the last month * pregnancy * breastfeeding the last 3 months * unstable body weight the last 3 months * high intensity training \> 3 times weekly

Keywords: methionine cysteine sulfur amino acids dietary intervention plant-based diet
pressure injury prevention by intermittent electrical stimulation

Conditions: Pressure Injury

Summary: the proposed study assesses the superiority of ies supplementation to the standard of care alone (offloading pressure every two hours) in improving the prevention and treatment of sacral and ischial pressure injuries.


Eligibility criteria:
inclusion criteria: 1. modified braden scale score of 14 or less. the modified braden scale score is calculated as follows: braden scale score (ranges from 6 to 23) * 1 for low serum albumin * 1 for type ii diabetes 2. anticipated length of stay of at least 4 days 3. bmi \< 35 4. participants capable of giving informed consent, or if appropriate, participants having an acceptable individual capable of giving consent on the participant's behalf. exclusion criteria: 1. existing pressure injuries above stage ii and injuries classified as dti or unstageable 2. neuromuscular blocking drugs \& myasthenia gravis: may prevent the ability of electrical stimulation to induce muscular contraction 3. unstable spinal, pelvic, or hip fractures that may be displaced by a forced contraction 4. rhabdomyolysis 5. use of a pacemaker 6. skin breakdown over the gluteal regions that would preclude the use of surface electrodes.
pilot study to determine radioiodide accumulation and dosimetry in breast cancers using 124i pet/ct

Conditions: Breast Cancer; Breast Cancer Early Stage Breast Cancer (Stage 1-3); Breast Cancer Metastatic Breast Cancer

Summary: this is a pilot imaging study for women whose tumors express nis \[na+i- symporter, sodium iodide symporter\]. eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in \> 20% of cells as determined by immunohistochemical methods. a total of 10 patients will be imaged with 124i pet/ct (serial scans over 24 hour period) to determine radioiodide uptake and distribution in tumor tissue. thyroid iodide uptake and retention will be blocked beginning one week prior to 124i pet/ct scan with thyroid hormone (t3) and methimazole (impedes organification). tumor, organ and whole body dosimetry will be calculated in each patient.


Eligibility criteria:
inclusion criteria:1. stage i-iv breast cancer. patients must have clinical or radiographic evidence of localized or metastatic disease. 2. criteria for nis-positivity are defined as: \>= 20% of cells with plasma membrane and/or strong intracellular/plasma membrane immunoreactivity 3. any previous therapy including radiation therapy is allowable. 4. women 18 years of age or older. 5. patients must have a life expectancy of at least 3 months 6. patients with ecog performance status 0-3 will be eligible. 7. if on chemotherapy, thyroid suppression should be initiated no sooner than two weeks after last chemotherapy cycle. 8. ability to understand and willingness to sign a written informed consent document. 9. discontinuation of hormonal or biological therapies for the 10 days of the study is preferred but not mandated. 10. laboratory tests (cbc, comprehensive metabolic panel) must be performed within 120 day prior to study initiation. exclusion criteria:1. history of metastatic thyroid cancer 2. exclude the use of cytotoxic, hormonal or biological agents for one week prior to and during imaging. 3. pregnant or nursing patients will be excluded from the study as iodide can accumulate in the breast and is transported across the placenta. 4. inability to tolerate thyroid hormone and/or methimazole pre-imaging treatment. 5. history of thyroid cancer (because patient could have concomitant thyroid cancer metastases and therefore competitively concentrate radioiodides) 6. psychiatric or addictive disorders that are not adequately controlled and would preclude obtaining informed consent. 7. patients with heart disease or other significant cardiac risk factors will be excluded from receiving thyroid suppressive therapy so as to avoid precipitating a cardiac arrhythmia.